InnoCare climbs 6%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

InnoCare Pharma (9969.HK) climbed nearly 6% in Hong Kong trading to HK$11.77.

The stock is down 6.36% over the past ten sessions and sits 21.97% above its 52-week low of HK$9.650.

The Hang Seng Index is up 2.72% over the past five sessions and down 7.44% year to date.

The biotechnology industry index rose 6.0% over the same period.

The company reported first-three-quarter revenue of 2.099 billion yuan, up 88.21% from a year earlier, and net income of 648 million yuan, swinging to a profit.

Separately, ICP-B161, a novel bispecific antibody targeting TL1A and IL-23p19 developed for inflammatory bowel disease and other autoimmune conditions, has completed first-patient dosing in a Phase I trial. InnoCare also presented clinical data at the ESMO Congress showing an 89.5% response rate for orelabrutinib-based combination therapy in treatment-naive marginal zone lymphoma patients.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.